SLN vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ARAV, ACABW, BFRIW, BTMDW, and BCTXW
Should you be buying Silence Therapeutics stock or one of its competitors? The main competitors of Silence Therapeutics include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), ARAVIVE (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), and BriaCell Therapeutics (BCTXW). These companies are all part of the "pharmaceutical products" industry.
Silence Therapeutics vs. Its Competitors
Silence Therapeutics (NASDAQ:SLN) and 180 Life Sciences (NASDAQ:ATNFW) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.
98.7% of Silence Therapeutics shares are owned by institutional investors. 4.1% of Silence Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
180 Life Sciences has a net margin of 0.00% compared to Silence Therapeutics' net margin of -294.20%. 180 Life Sciences' return on equity of 0.00% beat Silence Therapeutics' return on equity.
Silence Therapeutics presently has a consensus target price of $33.83, suggesting a potential upside of 500.95%. Given Silence Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Silence Therapeutics is more favorable than 180 Life Sciences.
In the previous week, Silence Therapeutics had 2 more articles in the media than 180 Life Sciences. MarketBeat recorded 7 mentions for Silence Therapeutics and 5 mentions for 180 Life Sciences. 180 Life Sciences' average media sentiment score of 0.98 beat Silence Therapeutics' score of -0.17 indicating that 180 Life Sciences is being referred to more favorably in the news media.
180 Life Sciences has lower revenue, but higher earnings than Silence Therapeutics.
Summary
Silence Therapeutics beats 180 Life Sciences on 7 of the 11 factors compared between the two stocks.
Get Silence Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Silence Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SLN) was last updated on 8/15/2025 by MarketBeat.com Staff
MarketBeat All Access